AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$VRAX

Virax Biolabs Group Ltd

Price · $VRAXvia TradingView
AI sentiment · 7d1 articles
MAY 21net (bullish − bearish)MAY 27
Bullish
1
Neutral
0
Bearish
0
Insider · 30dFeed →

No SEC Form 4 filings for $VRAX in the last 30 days.

Top stories · $VRAXMore →
MAY 26·prnewswire.comMed

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes

Virax Biolabs (NASDAQ: VRAX) reported early pilot data for ViraxImmune™, a blood-based test in development for Long COVID, ME/CFS and related post-acute infection syndromes. In the pilot dataset, it reported 88% specificity and 92% positive predictive value separating PAIS patients from healthy controls. The company said it has evaluated the test in 120+ subjects in an ongoing UK study and plans larger validation using samples from 300 additional participants starting Q4 2026, with results expec

APR 10·Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session

This article lists 12 healthcare stocks that experienced significant movement in Friday's after-market trading session. Gainers include Virax Biolabs Group (VRAX), IDEAYA Biosciences (IDYA), Allogene Therapeutics (ALLO), Oncolytics Biotech (ONCY), PureTech Health (PRTC), and PharmaCyte Biotech (PMCB). Losers include Wellgistics Health (WGRX), Nasus Pharma (NSRX), Vivos Therapeutics (VVOS), Estrella Immunopharma (ESLA), Geovax Labs (GOVX), and Profusa (PFSA), with specific percentage changes and market caps provided for each.

News on $VRAX

All news →